Alligator CEO Discusses Pipeline Additions, Milestone Expectations And The IO Deal Landscape

Alligator Bioscience’s Per Norlen discusses the latest addition to its pipeline, a first-in-class bispecific tumor-localized antibody targeting the checkpoint inhibitor CTLA-4.

Video interview
• Source: Shutterstock

Speaking to Scrip on the sidelines of BIO-Europe in Copenhagen Alligator Bioscience AB’s CEO, Per Norlen, described the latest addition to the small Swedish cancer specialist’s pipeline, a bispecific antibody, ATOR-1144, which is a dual immune activator targeting CTLA-4 and GITR.

ATOR-1144 works through several pathways, including activation of T-cells, depletion of regulatory T-cells, and activation of NK cells, for enhanced...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip

Rocket Comes Back To Earth With Restructuring Plan

 

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.